發(fā)布時(shí)間：2018-01-29 23:13

  本文關(guān)鍵詞： CCL18 鼻咽癌 遷移 化療耐藥　出處：《重慶醫(yī)科大學(xué)》2013年碩士論文　論文類型：學(xué)位論文

【摘要】：目的：研究趨化因子配體18（CCL18）在體外對(duì)人鼻咽癌細(xì)胞株增殖、遷移能力和化療耐藥性的影響，探討其臨床意義。 方法：以人鼻咽癌細(xì)胞株HNE-1為研究對(duì)象，通過(guò)用噻唑藍(lán)(MTT)比色法檢測(cè)不同濃度的重組CCL18對(duì)細(xì)胞增殖能力的影響。用Transwell小室體外遷移系統(tǒng)檢測(cè)CCL18對(duì)鼻咽癌細(xì)胞的趨化作用。將細(xì)胞與CCL18共培育后，加入不同濃度的順鉑，，用MTT比色法檢測(cè)細(xì)胞的半數(shù)存活量（LD50），分析CCL18對(duì)鼻咽癌細(xì)胞化療耐藥的影響。 結(jié)果：不同濃度的CCL18與鼻咽癌細(xì)胞共同培育后，CCL18對(duì)鼻咽癌細(xì)胞的增殖無(wú)明顯促進(jìn)作用（P＞0.05）。在趨化實(shí)驗(yàn)中，不同濃度的重組CCL18的各組均能能提高細(xì)胞活動(dòng)能力，促進(jìn)細(xì)胞的遷移（P＜0.05），較對(duì)照組有明顯促使細(xì)胞穿膜的作用(P＜0.05)，并呈現(xiàn)濃度依賴性。經(jīng)CCL18處理的鼻咽癌細(xì)胞對(duì)順鉑治療的敏感性降低，CCL18濃度升高后，達(dá)到相同的細(xì)胞半數(shù)致死量需要更高濃度的順鉑，CCL18提高了細(xì)胞對(duì)順鉑的化療耐藥性。 結(jié)論：CCL18可作為鼻咽癌的生物學(xué)標(biāo)志物，其表達(dá)與鼻咽癌的侵襲轉(zhuǎn)移和化療耐藥性相關(guān)，對(duì)鼻咽癌的診斷、治療和預(yù)后判斷有一定臨床意義。
[Abstract]:Aim: to study the effects of chemokine ligand 18CCL18 on proliferation, migration and chemotherapeutic resistance of human nasopharyngeal carcinoma cell line in vitro. Methods: human nasopharyngeal carcinoma cell line HNE-1 was studied. By using thiazolyl blue (MTT). The effect of different concentrations of recombinant CCL18 on cell proliferation was detected by colorimetric assay. The chemotaxis of CCL18 on nasopharyngeal carcinoma cells was detected by Transwell chamber migration system in vitro. CL18 co-culture. The effect of CCL18 on chemotherapeutic resistance of nasopharyngeal carcinoma cells was analyzed by MTT colorimetric assay. Results: after different concentrations of CCL18 and nasopharyngeal carcinoma cells were co-cultured, CCL18 had no significant effect on the proliferation of nasopharyngeal carcinoma cells (P > 0.05). Different concentrations of recombinant CCL18 could improve cell activity and promote cell migration (P < 0.05), which was more effective than that of control group (P < 0.05). The sensitivity of nasopharyngeal carcinoma cells treated with CCL18 to cisplatin treatment decreased after the concentration of CCL18 increased, and reached the same cell half lethal dose required a higher concentration of cisplatin. CCL18 increases the chemotherapeutic resistance of cells to cisplatin. Conclusion the expression of 1% CCL18 may be a biomarker of nasopharyngeal carcinoma, and its expression is related to invasion, metastasis and chemotherapeutic resistance of nasopharyngeal carcinoma. It has some clinical significance in the diagnosis, treatment and prognosis of nasopharyngeal carcinoma.
【學(xué)位授予單位】：重慶醫(yī)科大學(xué)
【學(xué)位級(jí)別】：碩士
【學(xué)位授予年份】：2013
【分類號(hào)】：R739.63

【參考文獻(xiàn)】

相關(guān)期刊論文 前2條

1 李偉棟;魏礦榮;雷風(fēng);梁志恒;劉靜;張晉昕;;中山市鼻咽癌流行病學(xué)危險(xiǎn)因素探究[J];中華疾病控制雜志;2012年06期

2 ;Chemokines and hepatocellular carcinoma[J];World Journal of Gastroenterology;2010年15期

本文編號(hào)：1474611